JP4339702B2 - Cetp活性及び心臓病治療(剤)の効力(有効性)の生体外測定方法 - Google Patents
Cetp活性及び心臓病治療(剤)の効力(有効性)の生体外測定方法 Download PDFInfo
- Publication number
- JP4339702B2 JP4339702B2 JP2003584334A JP2003584334A JP4339702B2 JP 4339702 B2 JP4339702 B2 JP 4339702B2 JP 2003584334 A JP2003584334 A JP 2003584334A JP 2003584334 A JP2003584334 A JP 2003584334A JP 4339702 B2 JP4339702 B2 JP 4339702B2
- Authority
- JP
- Japan
- Prior art keywords
- cetp
- activity
- sample
- acceptor
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Description
Claims (14)
- 被検体の体液中のコレステリルエステル転送タンパク質(CETP)活性測定方法であって、
被検体から採取した体液のサンプルと、標識CETP基質を含みかつアポA-Iを含有しないドナーと、該基質がCETP活性によって転送されて来られ得るアクセプターと、を接触して反応混合溶液を生成すること、ここに、該反応混合溶液の少なくとも凡そ89%v/vは該体液のサンプルであること、及び
前記ドナーから前記アクセプターへの前記基質の転送を検出して前記体液中のCETPの活性を測定すること、ここに、前記体液のサンプルは内因性CETP阻害剤又は賦活剤を含むこと、
を含む方法。 - 前記基質は、自己消光蛍光分子で標識されている請求項1に記載の方法。
- 前記自己消光蛍光分子は、N-(7-ニトロベンズ-2-オキサ-1,3-ジアゾール-4-イル)アミノ(NBD)、5-ブチル-4,4-ジフルオロ-4-ボラ-3a,4a-ジアザ-s-インダセン、フルオレセイン、ダンシル、又はローダミンである請求項2に記載の方法。
- 前記分子は、NBDである請求項3に記載の方法。
- 前記基質は、コレステリルエステル、トリアシルグリセロール、又はトリグリセリドである請求項1〜4の何れか1項に記載の方法。
- 前記基質は、リノール酸コレステリルである請求項5に記載の方法。
- 前記アクセプターは、アポB含有リポタンパク質である請求項1〜6の何れか1項に記載の方法。
- 前記サンプルは、凍結されている請求項1〜7の何れか1項に記載の方法。
- 標準から、転送された基質の量を(コンピュータで)計算することを更に含む請求項1〜8の何れか1項に記載の方法。
- 前記アクセプターに組み込まれた標識の量の前記測定は、前記反応混合溶液から該アクセプターを分離することなく該反応混合溶液において実行される請求項1〜9の何れか1項に記載の方法。
- CETP活性のレベルと、心臓病、アテローム性動脈硬化症、低αリポタンパク血症、プラズマアポA−I対アポBの異常割合、アポB含有タンパク質のレベル上昇、冠動脈硬化症、糖尿病及び/又は肥満症に関する危険因子の存在を指示する予め決定された基準値と比較することを更に含む請求項1〜10の何れか1項に記載の方法。
- CETP活性のレベルと、前記サンプル中のCETPタンパク質の量又は活性に影響を及ぼすCETPをコードする遺伝子における遺伝的欠陥の存在を指示する予め決定された基準値と比較することを更に含む請求項1〜10の何れか1項に記載の方法。
- 前記被検体は、CETP活性阻害剤の投与により処置され、かつ前記体液は、前記CETP阻害剤を含有する、及び/又は
前記被検体は、生理的CETP活性に影響を及ぼす非アテローム生成食餌改良療法により処置されている
請求項1〜10の何れか1項に記載の方法。 - 前記阻害剤は、コレステロール合成及び/又は転送を阻害し、CETP発現を阻害し、又はアテローム性動脈硬化症の治療に使用される請求項13に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37262802P | 2002-04-11 | 2002-04-11 | |
PCT/US2003/011443 WO2003087396A1 (en) | 2002-04-11 | 2003-04-11 | Ex vivo method for determination of cetp activity and efficacy of heart disease treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005522220A JP2005522220A (ja) | 2005-07-28 |
JP4339702B2 true JP4339702B2 (ja) | 2009-10-07 |
Family
ID=29250882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003584334A Expired - Fee Related JP4339702B2 (ja) | 2002-04-11 | 2003-04-11 | Cetp活性及び心臓病治療(剤)の効力(有効性)の生体外測定方法 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7279297B2 (ja) |
EP (1) | EP1492880B1 (ja) |
JP (1) | JP4339702B2 (ja) |
AT (1) | ATE410521T1 (ja) |
AU (1) | AU2003230916A1 (ja) |
CA (1) | CA2480439C (ja) |
DE (1) | DE60323954D1 (ja) |
WO (1) | WO2003087396A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1444359A4 (en) * | 2001-10-23 | 2007-04-25 | Cardiovascular Targets Inc | TEST FOR PHOSPHOLIPID TRANSFER PROTEIN (PLTP) ACTIVITY |
WO2012074855A2 (en) * | 2010-11-22 | 2012-06-07 | The Regents Of The University Of California | Methods of identifying a cellular nascent rna transcript |
WO2013116371A1 (en) * | 2012-01-30 | 2013-08-08 | Roar Biomedical Inc. | Ex vivo plasma enzyme activity assay using inhibitors as a negative control |
CN107024590A (zh) * | 2017-03-13 | 2017-08-08 | 新疆医科大学 | 一种诊断1型和2型糖尿病的血清蛋白标志物组 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0618803A4 (en) * | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
US5585235A (en) * | 1993-04-13 | 1996-12-17 | Diagnescent Technologies, Inc. | Fluorescent assay and method that corrects for spectral interference |
US5618683A (en) * | 1993-04-13 | 1997-04-08 | Brocia; Robert W. | Diagnostic kit for cholesteryl ester transfer protein (CETP) activity measurement and a new synthetic particle used therein |
US6174693B1 (en) * | 1998-01-12 | 2001-01-16 | Robert W Brocia | Immunological assay for protein activity |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
-
2003
- 2003-04-11 JP JP2003584334A patent/JP4339702B2/ja not_active Expired - Fee Related
- 2003-04-11 US US10/413,419 patent/US7279297B2/en not_active Expired - Lifetime
- 2003-04-11 CA CA2480439A patent/CA2480439C/en not_active Expired - Fee Related
- 2003-04-11 WO PCT/US2003/011443 patent/WO2003087396A1/en active Application Filing
- 2003-04-11 AT AT03724023T patent/ATE410521T1/de not_active IP Right Cessation
- 2003-04-11 DE DE60323954T patent/DE60323954D1/de not_active Expired - Lifetime
- 2003-04-11 EP EP03724023A patent/EP1492880B1/en not_active Expired - Lifetime
- 2003-04-11 AU AU2003230916A patent/AU2003230916A1/en not_active Abandoned
-
2007
- 2007-10-09 US US11/869,655 patent/US7642065B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2005522220A (ja) | 2005-07-28 |
ATE410521T1 (de) | 2008-10-15 |
US7642065B2 (en) | 2010-01-05 |
CA2480439A1 (en) | 2003-10-23 |
US20040018578A1 (en) | 2004-01-29 |
WO2003087396A1 (en) | 2003-10-23 |
EP1492880A4 (en) | 2006-10-11 |
CA2480439C (en) | 2012-08-21 |
US20080085530A1 (en) | 2008-04-10 |
US7279297B2 (en) | 2007-10-09 |
EP1492880B1 (en) | 2008-10-08 |
EP1492880A1 (en) | 2005-01-05 |
DE60323954D1 (de) | 2008-11-20 |
AU2003230916A1 (en) | 2003-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5770355A (en) | Heart disease test kit and method of determining a heart disease risk factor and efficacy of a treatment for heart disease | |
Coleman et al. | Localization, purification, and functional reconstitution of the P4-ATPase Atp8a2, a phosphatidylserine flippase in photoreceptor disc membranes | |
Franck et al. | Insulin-induced GLUT4 translocation to the plasma membrane is blunted in large compared with small primary fat cells isolated from the same individual | |
Solnica et al. | 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders | |
Abou Sawan et al. | Whole egg, but not egg white, ingestion induces mTOR colocalization with the lysosome after resistance exercise | |
US10295551B2 (en) | Development and use of fluorescent probes of unbound bilirubin | |
US7851223B2 (en) | Method to detect emphysema | |
Cain et al. | Endothelin-1–induced enhancement of coronary smooth muscle contraction via MAPK-dependent and MAPK-independent [Ca2+] i sensitization pathways | |
Nofer et al. | Apolipoprotein AI activates Cdc42 signaling through the ABCA1 transporter | |
Wang et al. | Hypoxia inhibits myosin phosphatase in pulmonary arterial smooth muscle cells: role of Rho-kinase | |
CN102597781B (zh) | 判定高功能自闭症的发病危险度的方法及标记物 | |
US7642065B2 (en) | Ex vivo method for determination of CETP activity and efficacy of heart disease treatment | |
US7906300B2 (en) | Methods for diagnosing an attention-deficit/Hyperactivity disorder | |
Greube et al. | Interaction of fibronectin type II proteins with membranes: the stallion seminal plasma protein SP-1/2 | |
Péterfy et al. | Characterization of two novel pathogenic variants at compound heterozygous status in lipase maturation factor 1 gene causing severe hypertriglyceridemia | |
US20180179574A1 (en) | Systems and methods for characterization of hypertriglyceridemia | |
US7060452B2 (en) | Assay method for measurement of net cholesterol flux | |
Fišar et al. | Measurement of Mitochondrial Respiration in Platelets | |
Shao et al. | Functional analysis of misfolded transthyretin extracted from abnormal vitreous with high myopia related ocular pathologies | |
Ferretti et al. | Abnormalities of plasma lipoprotein composition and fluidity in psoriasis. | |
Hunter et al. | Lysophosphatidylcholine modulates catalytically important motions of the Ca-ATPase phosphorylation domain | |
Höfer et al. | Use of liposomes for studying interactions of soluble proteins with cellular membranes | |
McGuire et al. | Studying KcsA channel clustering using single channel voltage-clamp fluorescence imaging | |
US7618784B2 (en) | Assay for phospholipid transfer protein (PLTP) activity | |
Julius et al. | Lipid transfer protein activities in subjects with impaired glucose tolerance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050329 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081104 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090204 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090304 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090311 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090324 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090609 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090702 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4339702 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120710 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120710 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130710 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |